Q3 EPS Estimates for Organigram Reduced by Atb Cap Markets

Organigram Holdings Inc. (TSE:OGI - Free Report) - Equities researchers at Atb Cap Markets dropped their Q3 2025 earnings per share estimates for Organigram in a report released on Tuesday, February 11th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings of ($0.03) per share for the quarter, down from their previous estimate of ($0.02). The consensus estimate for Organigram's current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram's Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.00 EPS.

OGI has been the subject of a number of other reports. Canaccord Genuity Group cut their target price on Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating for the company in a research report on Monday, December 9th. ATB Capital cut their price objective on Organigram from C$5.25 to C$3.50 in a research report on Tuesday, December 17th.

Organigram Price Performance

OGI traded up C$0.12 during trading on Friday, reaching C$1.93. The stock had a trading volume of 475,962 shares, compared to its average volume of 303,282. The firm has a market capitalization of C$238.44 million, a price-to-earnings ratio of -4.08, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07. Organigram has a 1-year low of C$1.80 and a 1-year high of C$3.95. The stock has a 50 day moving average of C$2.22 and a two-hundred day moving average of C$2.31.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.